Genmab needs to continue Phase III trial of anticancer zalutumumab
This article was originally published in Scrip
Genmabwill not be able to stop the pivotal Phase III head and neck cancer trial of its experimental monoclonal antibody zalutumumab (HuMax-EGFr) early, but the Danish biotech company said it still remains optimistic that the drug will show a survival benefit in the final study analysis.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.